欧洲人类生物检体市场：分析与预测（2025-2035）

欧洲人类生物检体市场规模预计将从 2025 年的 8.818 亿美元成长到 2035 年的 19.466 亿美元，在 2025-2035 年预测期内的复合年增长率为 8.24%。

人体组织、血液、体液和分子衍生物是用于科学和医学研究的人体生物材料。它们保留了真实世界的疾病特征，对于研究分子路径、检验诊断方法和开发个人化治疗方案至关重要。透过标准化的采集、处理和储存，生物样本能够保持其完整性并将其与临床数据关联起来，从而促进严谨的转化研究，并推动精准医学的进步。

市场概览

欧洲人类生物检体市场在推动该地区的生物医学研究、药物研发和精准医疗方面发挥关键作用。组织、血液、体液及其衍生样本是人类生物检体的重要组成部分，对于阐明疾病机制、识别生物标记和开发个人化治疗方案至关重要。欧洲拥有完善的医疗保健体系、广泛的医院网络和值得信赖的学术研究机构，为生物样本的采集和利用提供了坚实的基础，尤其是在肿瘤学、罕见疾病和转化医学研究领域。

对品质、可追溯性和伦理管治的高度重视是欧洲生物样本环境的显着特征。众多由各国政府和欧盟资助计划支持的公共和人群生物样本库，确保了获取註释完善且具有临床意义的样本。精准医疗和多体学研究日益增长的需求，使得与遗传、临床和生活方式数据关联的纵向生物样本变得至关重要。数位化生物银行平台能够同时提升资料整合、知情同意追踪和样本管理效率。

欧洲拥有严格的监管和高度的科学信誉，但其市场结构也较为复杂。严格的资料隐私规则、国家生物银行法规以及高昂的营运成本可能会限制其可及性和扩充性。然而，对生物银行基础设施的持续投资、跨国合作以及标准化工作，已使欧洲人类生物检体市场在促进生命科学创新方面占据了战略优势。

市场区隔:

细分 1：按地区

• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲国家

欧洲人类生物检体市场趋势、驱动因素与挑战

市场趋势

• 对高品质、註释完善且与临床和分子数据相符的生物样本的需求不断增长。
• 在西欧和北欧扩大基于人群和疾病特异性的生物样本库。
• 纵向和多体学相容的生物样本正日益受到关注，以支持精准医疗。
• 扩大数位生物样本库管理系统在可追溯性、同意追踪和数据整合方面的应用。
• 加强学术生物样本库、医院、合约研究组织和製药公司之间的合作。

主要市场驱动因素

• 肿瘤学、免疫学和罕见疾病研究领域发展迅速，需要人类来源的样本。
• 欧洲对个人化和精准医疗方法的接受度越来越高。
• 欧洲主要市场增加医药和生技研发投入。
• 公共资金和欧盟层面的倡议，以促进转化研究和生物银行的建立。
• 监管机构对样品品质、标准化和道德采购的重视提高了可靠性和利用率。

主要挑战

• GDPR 和国家生物银行库法律规定的严格监管和道德要求。
• 欧洲各国在知情同意框架和样本取得规则方面存在差异。
• 与检体采集、储存、品管和合规相关的营运成本很高。
• 罕见疾病和高度特异性生物检体的有限供应。
• 生物样本库与临床和基因组资料库之间资料整合的挑战。

产品与创新策略：本报告深入分析了人类生物检体领域的最新技术进展，使各组织能够推动创新并开发符合市场需求的尖端产品。

成长与行销策略：透过全面的市场分析与关键成长机会的识别，我们为企业提供製定有针对性的行销策略并有效扩大市场份额所需的知识。

竞争策略：该报告包含全面的竞争格局分析，以帮助企业了解竞争对手的优势和劣势，并制定有效的策略以获得市场竞争优势。

监管和合规策略：提供有关不断变化的法规结构、核准流程和行业指南的最新信息，以确保您的组织保持合规，并加速新的人类生物检体进入市场。

投资和业务扩大策略：透过分析市场趋势、资金筹措模式和合作机会，我们帮助企业做出明智的投资决策，并识别潜在的併购机会以促进业务成长。

目录

执行摘要

第一章 欧洲人类生物检体市场：产业展望

• 市场概览
  • 市场概况及趋势
• 市场趋势
  • 影响分析
  • 增加产品发布和监管核准
  • 加强参与企业、政府机构和学术机构之间的合作
• 供应链概览
• 监管状态
  • 欧洲
• 市场动态
  • 驱动因素、限制因素和机会：评估当前和未来的影响
  • 市场驱动因素
  • 市场限制
  • 市场机会

第二章 区域

• 区域概况
• 欧洲
  • 区域概览
  • 市场成长驱动因素
  • 成长抑制因素
  • 市场规模及预测
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 其他的

第三章 竞争标竿分析与公司概况

• 关键发展分析（依公司划分），2020-2025 年
• 公司简介
  • Logical Biological
  • Europa Biosite
  • Grifols, SA

第四章调查方法

This report can be delivered in 2 working days.

Introduction to Europe Human Biospecimen Market

The Europe human biospecimen market is projected to reach $1,946.6 million by 2035 from $881.8 million in 2025, growing at a CAGR of 8.24% during the forecast period 2025-2035. Human tissues, blood, biofluids, and molecular derivatives are examples of biological materials that are extracted from the human body for use in scientific and medical research. They are crucial for researching molecular pathways, verifying diagnostics, and creating tailored treatments because they preserve the features of real-world diseases. Biospecimens facilitate precise translational research and propel advances in precision medicine through standardized collection, processing, and storage that maintain integrity and connect clinical data.

Market Introduction

The Europe human biospecimen market plays a critical role in advancing biomedical research, drug discovery, and precision medicine across the region. Tissues, blood, biofluids, and derived samples are examples of human biospecimens that are crucial for comprehending disease mechanisms, confirming biomarkers, and creating tailored treatments. Europe offers a solid basis for the collection and use of biospecimens, especially in oncology, rare illnesses, and translational research, thanks to its robust healthcare systems, vast hospital networks, and reputable academic research institutes.

The focus on quality, traceability, and ethical governance is a defining feature of the biospecimen landscape in Europe. Access to well-annotated, clinically relevant samples is ensured by the region's many public and population-based biobanks, which are backed by national governments and EU-funded projects. The need for longitudinal biospecimens connected to genetic, clinical, and lifestyle data is being driven by the growing demand for precision medicine and multi-omics research. Digital biobanking platforms are simultaneously enhancing data integration, consent tracking, and sample management.

Europe has strict regulations and strong scientific credibility, but the market is also structurally complex. Accessibility and scalability may be restricted by stringent data privacy rules, national biobanking regulations, and significant operating expenses. Nonetheless, the European market for human biospecimens is positioned as a strategically significant facilitator of life sciences innovation due to ongoing investments in biobanking infrastructure, cross-border cooperation, and standardization activities.

Market Segmentation:

Segmentation 1: By Region

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe

Europe Human Biospecimen Market Trends, Drivers and Challenges

Market Trends

• Rising demand for high-quality, well-annotated biospecimens aligned with clinical and molecular data.
• Expansion of population-based and disease-specific biobanks across Western and Northern Europe.
• Increased focus on longitudinal and multi-omics-ready biospecimens to support precision medicine.
• Greater use of digital biobank management systems for traceability, consent tracking, and data integration.
• Growing collaboration between academic biobanks, hospitals, CROs, and pharmaceutical companies.

Key Market Drivers

• Strong growth in oncology, immunology, and rare disease research requiring human-derived samples.
• Increasing adoption of personalized and precision medicine approaches in Europe.
• Rising pharmaceutical and biotech R&D spending across major European markets.
• Supportive public funding and EU-level initiatives promoting translational research and biobanking.
• Regulatory emphasis on sample quality, standardization, and ethical sourcing, increasing trust and utilization.

Major Challenges

• Stringent regulatory and ethical requirements under GDPR and national biobanking laws.
• Variability in consent frameworks and sample access rules across European countries.
• High operational costs related to sample collection, storage, quality control, and compliance.
• Limited availability of rare disease and highly specific biospecimens.
• Data integration challenges between biospecimen repositories and clinical or genomic databases.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in human biospecimens, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new human biospecimens.

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Table of Contents

Executive Summary

Scope and Definition

1 Europe Human Biospecimen Market: Industry Outlook

• 1.1 Market Overview
  • 1.1.1 Market Overview and Market Trends
• 1.2 Market Trends
  • 1.2.1 Impact Analysis
  • 1.2.2 Increasing Product Launches and Regulatory Approvals
  • 1.2.3 Increasing Collaboration between Players, Government Bodies, and Academia
• 1.3 Supply Chain Overview
• 1.4 Regulatory Landscape
  • 1.4.1 Europe
    • 1.4.1.1 Germany
    • 1.4.1.2 U.K.
• 1.5 Market Dynamics
  • 1.5.1 Drivers, Restraints, and Opportunities: Current and Future Impact Assessment
  • 1.5.2 Market Drivers
    • 1.5.2.1 Rising Adoption of Annotated Human Biospecimens
    • 1.5.2.2 Expansion of Biobanks and National Population Genomics Programs
    • 1.5.2.3 Surge in Cell and Gene Therapies, CAR-T, and Advanced Modalities
  • 1.5.3 Market Restraints
    • 1.5.3.1 Pre-Analytical Variability and Poor Biospecimen Quality
    • 1.5.3.2 Logistical, Storage, and Operational Challenges across the Biospecimen Lifecycle
  • 1.5.4 Market Opportunities
    • 1.5.4.1 Commercialization of Disease-Specific Rare-Disease Cohorts

2 Region

• 2.1 Regional Summary
• 2.2 Europe
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 Market Sizing and Forecast
  • 2.2.5 U.K.
    • 2.2.5.1 Country Overview
    • 2.2.5.2 Market Sizing and Forecast
  • 2.2.6 Germany
    • 2.2.6.1 Country Overview
    • 2.2.6.2 Market Sizing and Forecast
  • 2.2.7 France
    • 2.2.7.1 Country Overview
    • 2.2.7.2 Market Sizing and Forecast
  • 2.2.8 Italy
    • 2.2.8.1 Country Overview
    • 2.2.8.2 Market Sizing and Forecast
  • 2.2.9 Spain
    • 2.2.9.1 Country Overview
    • 2.2.9.2 Market Sizing and Forecast
  • 2.2.10 Rest-of-the- Europe
    • 2.2.10.1 Country Overview
    • 2.2.10.2 Market Sizing and Forecast

3 Competitive Benchmarking and Company Profiles

• 3.1 Key Developments Analysis (by Company), 2020-2025
• 3.2 Company Profiles
  • 3.2.1 Logical Biological
    • 3.2.1.1 Overview
  • 3.2.2 Europa Biosite
    • 3.2.2.1 Overview
  • 3.2.3 Grifols, S.A.
    • 3.2.3.1 Overview

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Inclusion and Exclusion
  • 4.1.4 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1: Europe Human Biospecimen Market (by Scenario), $Million, 2024, 2028, and 2035
• Figure 2: Europe Human Biospecimen Market, 2024 and 2035
• Figure 3: Europe Human Biospecimen Market Snapshot
• Figure 4: Human Biospecimen Market, $Million, 2024 and 2035
• Figure 5: Supply Chain Flow
• Figure 6: Europe Human Biospecimen Market, $Million, 2024-2035
• Figure 7: U.K. Human Biospecimen Market, $Million, 2024-2035
• Figure 8: Germany Human Biospecimen Market, $Million, 2024-2035
• Figure 9: France Human Biospecimen Market, $Million, 2024-2035
• Figure 10: Italy Human Biospecimen Market, $Million, 2024-2035
• Figure 11: Spain Human Biospecimen Market, $Million, 2024-2035
• Figure 12: Rest-of-Europe Human Biospecimen Market, $Million, 2024-2035
• Figure 13: Inclusion and Exclusion Criteria for the Europe Human Biospecimen Market
• Figure 14: Data Triangulation
• Figure 15: Top-Down and Bottom-Up Approach
• Figure 16: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Key Market Trends
• Table 3: Product Launches and Regulatory Approvals in the Human Biospecimen Market
• Table 4: Collaborations in the Human Biospecimen Market
• Table 5: Human Biospecimen Market (by Region), $Million, 2024-2035
• Table 6: Key Strategies and Developments, 2020-2025